Literature DB >> 12664976

Spatial heterogeneity and temporal kinetics of photosensitizer (AlPcS2) concentration in murine tumors RIF-1 and MTG-B.

Claudia C Lee1, Brian W Pogue, Julia A O'Hara, Carmen M Wilmot, Rendy R Strawbridge, Gregory C Burke, P Jack Hoopes.   

Abstract

In this study we compared the photosensitizer concentration in two experimental murine tumors using an in situ fluorescence detection instrument to examine temporal and spatial variations, after intravenous versus intratumor injection. Also, the variations in the estimate as detected by large area sampling and micro-region sampling are compared, in order to determine what the inter-tissue and inter-animal variations are, and how the method of sampling affects this estimate. The latter study was carried out ex vivo in the same tumors, which had been harvested and frozen after in vivo measurements were made. The photosensitizer, disulphonated aluminum phthalocyanine (AlPcS2) was injected either intravenously (IV) or directly into the tumor (ITu), using two murine models, MTG-B (mammary adenocarcinoma) and RIF-1 (radiation-induced fibrosarcoma) grown subcutaneously on the flank. An in situ microsampling fluorescence probe was used to assess photosensitizer concentration, through real-time measurement of the remitted intensity. The photosensitizer concentration was evaluated at 8 time endpoints between 15 min and 48 h post-injection. Inter-tumor and intra-tumor variations were assessed by repeated samples from the tumor tissues. The average photosensitizer level reaches a peak between 3 to 6 h in both tumor and normal tissues using IV administration, but peaks within 1 h following ITu administration. MTG-B tumors demonstrated a factor of 2 higher uptake than RIF-1 tumors. The pharmacokinetic uptake rates of the RIF-1 tumor were 3 times faster than for MTG-B, while there was no statistical difference in their clearance rates. Preferential uptake of AlPcS2 by both tumors compared to contra-lateral flank subcutaneous normal tissue was documented, with ITu injection exceeding IV injection by a factor of 10 in the tumor to normal tissue ratio. Inter-animal standard deviation in the mean fluorescence was near 76% for both routes of administration, but estimates of the variation within tumor were near 16% standard deviation when a large sampling volume was used. In contrast, microscopic intra-tumor standard deviation in the mean estimate was near 76%, with IV injection, indicating that high heterogeneity exists in the photosensitizer concentration on a smaller distance scale. The inter-tumor variation was reduced by ITu injection, but at the expense of increasing intra-tumor variation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12664976     DOI: 10.1039/b207598a

Source DB:  PubMed          Journal:  Photochem Photobiol Sci        ISSN: 1474-905X            Impact factor:   3.982


  7 in total

1.  Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.

Authors:  Srivalleesha Mallidi; Sriram Anbil; Seonkyung Lee; Dieter Manstein; Stefan Elrington; Garuna Kositratna; David Schoenfeld; Brian Pogue; Steven J Davis; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2014-02       Impact factor: 3.170

2.  Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Authors:  Florencia Anatelli; Pawel Mroz; Qingde Liu; Changming Yang; Ana P Castano; Emilia Swietlik; Michael R Hamblin
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

3.  Explicit dosimetry for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a-mediated photodynamic therapy: macroscopic singlet oxygen modeling.

Authors:  Rozhin Penjweini; Baochang Liu; Michele M Kim; Timothy C Zhu
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

4.  Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-08-10       Impact factor: 3.631

5.  Explicit macroscopic singlet oxygen modeling for benzoporphyrin derivative monoacid ring A (BPD)-mediated photodynamic therapy.

Authors:  Michele M Kim; Rozhin Penjweini; Xing Liang; Timothy C Zhu
Journal:  J Photochem Photobiol B       Date:  2016-09-23       Impact factor: 6.252

6.  Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus.

Authors:  Brian W Pogue; Chao Sheng; Juan Benevides; David Forcione; Bill Puricelli; Norm Nishioka; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

7.  Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

Authors:  Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Stephen Chad Kanick; Scott C Davis; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Br J Cancer       Date:  2016-08-30       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.